Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Asset Writedowns and Impairment (2019 - 2022)

Standard Biotools (LAB) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with -$26000.0 as the latest value for Q4 2022.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to -$26000.0 in Q4 2022 year-over-year; TTM through Dec 2023 was $3.5 million, a 0.0% change, with the full-year FY2022 number at $3.5 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment was -$26000.0 for Q4 2022 at Standard Biotools, down from $3.5 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $3.5 million in Q2 2022 to a low of -$26000.0 in Q4 2022.